http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 17 Aug 2026 13:07:59 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Downgrades/Oppenheimer+Downgrades+AtaiBeckley+Inc+%28ATAI%29+to+Perform/26937151.html <p>Oppenheimer analyst Jay Olson downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Outperform to Perform.</p><p>For an analyst ratings summary and ratings history on AtaiBeckley Inc <a href="http://www.streetinsider.com/rating_history.php?q=ATAI">click here</a>. For more ratings news on AtaiBeckley Inc <a href="http://www.streetinsider.com/stock_lookup_news.php?q=ATAI&amp;type=analyst">click here</a>.</p><p>Shares of AtaiBeckley Inc closed at $7.26 yesterday.</p> http://www.streetinsider.com/Downgrades/Oppenheimer+Downgrades+AtaiBeckley+Inc+%28ATAI%29+to+Perform/26937151.html Mon, 17 Aug 2026 13:07:59 -0400 ATAI http://www.streetinsider.com/Downgrades/Deutsche+Bank+Downgrades+AtaiBeckley+Inc+%28ATAI%29+to+Hold/26907841.html <p>Deutsche Bank analyst David Hoang downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Hold with a price target of $8.00 (from $12.00).</p><p>The analyst comments: “ATAI reported financial results and published its 10-Q for 2Q26. Recall LLY announced a definitive agreement to acquire psychedelics drug developer ATAI on July 16, 2026. Under the terms of the agreement, LLY will acquire all outstanding shares of ATAI common stock for an upfront cash payment of $6.75 per share, representing an equity value of ~$2.8B and a ~40% premium to ATAI’s 30-day volume-weighted average trading price prior to deal announcement. The deal also includes http://www.streetinsider.com/Downgrades/Deutsche+Bank+Downgrades+AtaiBeckley+Inc+%28ATAI%29+to+Hold/26907841.html Wed, 12 Aug 2026 03:09:34 -0400 ATAI http://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Downgrades+AtaiBeckley+Inc+%28ATAI%29+to+Hold/26907841.html <p>Deutsche Bank analyst David Hoang downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Hold with a price target of $8.00 (from $12.00).</p><p>The analyst comments: “ATAI reported financial results and published its 10-Q for 2Q26. Recall LLY announced a definitive agreement to acquire psychedelics drug developer ATAI on July 16, 2026. Under the terms of the agreement, LLY will acquire all outstanding shares of ATAI common stock for an upfront cash payment of $6.75 per share, representing an equity value of ~$2.8B and a ~40% premium to ATAI’s 30-day volume-weighted average trading price prior to deal announcement. The deal also includes http://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Downgrades+AtaiBeckley+Inc+%28ATAI%29+to+Hold/26907841.html Wed, 12 Aug 2026 03:09:34 -0400 ATAI http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html <p>Helus Pharma (Nasdaq: HELP, Cboe CA: HELP), a clinical-stage company developing treatments for depression and anxiety, has appointed Michael Halstead as Chief Executive Officer, effective immediately, according to a statement from the company.</p> <p>Halstead previously served as President of Intra-Cellular Therapies, where he was involved in the launch and commercialization of CAPLYTA (lumateperone) and the company's $14.6 billion sale to Johnson &amp; Johnson (NYSE: JNJ) in 2025. Before that role, he held senior positions at Warner Chilcott, where he oversaw a $3 billion acquisition of Procter &amp; Gamble's pharmaceutical business in 2009 and the company's $8.5 billion sale to Actavis in http://www.streetinsider.com/FDA/Helus+Pharma+names+ex-Intra-Cellular+president+as+CEO/26871906.html Wed, 05 Aug 2026 10:26:01 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/Press+Releases/A+CEO+With+a+Proven+Track+Record+of+Success+in+Growing+and+Scaling+Biopharmaceutical+Companies+Just+Appointed+CEO+at+a+Clinical-Stage+Biotech%2C+Months+Before+Its+Pivotal+Phase+3+Readout/26871902.html <p>NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EVBnQJAQsrz9ukBZrfuPuBjVxM6i3OWBd4MRJKVWg4hKLDKGEf01sBMmQu0kgYoavoxMpwGjsak3drjd-H_UAEfD6hFAvD6jT4o8sPtfAA4=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>In biotech, the gap between a promising drug and a commercial success is often bridged by a single thing: the operator who has done it before. Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage company developing novel treatments for depression and anxiety, has just brought in exactly that kind of operator, appointing Michael Halstead, the former President of Intra-Cellular Therapies, as Chief Executive Officer, effective immediately. The move lands months before the company&apos;s first pivotal Phase 3 data readout, http://www.streetinsider.com/Press+Releases/A+CEO+With+a+Proven+Track+Record+of+Success+in+Growing+and+Scaling+Biopharmaceutical+Companies+Just+Appointed+CEO+at+a+Clinical-Stage+Biotech%2C+Months+Before+Its+Pivotal+Phase+3+Readout/26871902.html Wed, 05 Aug 2026 10:25:00 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/Press+Releases/A+CEO+With+a+Proven+Track+Record+of+Success+in+Growing+and+Scaling+Biopharmaceutical+Companies+Just+Appointed+CEO+at+a+Clinical-Stage+Biotech%2C+Months+Before+Its+Pivotal+Phase+3+Readout/26871902.html <p>NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EVBnQJAQsrz9ukBZrfuPuBjVxM6i3OWBd4MRJKVWg4hKLDKGEf01sBMmQu0kgYoavoxMpwGjsak3drjd-H_UAEfD6hFAvD6jT4o8sPtfAA4=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>In biotech, the gap between a promising drug and a commercial success is often bridged by a single thing: the operator who has done it before. Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage company developing novel treatments for depression and anxiety, has just brought in exactly that kind of operator, appointing Michael Halstead, the former President of Intra-Cellular Therapies, as Chief Executive Officer, effective immediately. The move lands months before the company&apos;s first pivotal Phase 3 data readout, http://www.streetinsider.com/Press+Releases/A+CEO+With+a+Proven+Track+Record+of+Success+in+Growing+and+Scaling+Biopharmaceutical+Companies+Just+Appointed+CEO+at+a+Clinical-Stage+Biotech%2C+Months+Before+Its+Pivotal+Phase+3+Readout/26871902.html Wed, 05 Aug 2026 10:25:00 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/Press+Releases/A+CEO+With+a+Proven+Track+Record+of+Success+in+Growing+and+Scaling+Biopharmaceutical+Companies+Just+Appointed+CEO+at+a+Clinical-Stage+Biotech%2C+Months+Before+Its+Pivotal+Phase+3+Readout/26871902.html <p>NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EVBnQJAQsrz9ukBZrfuPuBjVxM6i3OWBd4MRJKVWg4hKLDKGEf01sBMmQu0kgYoavoxMpwGjsak3drjd-H_UAEfD6hFAvD6jT4o8sPtfAA4=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>In biotech, the gap between a promising drug and a commercial success is often bridged by a single thing: the operator who has done it before. Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage company developing novel treatments for depression and anxiety, has just brought in exactly that kind of operator, appointing Michael Halstead, the former President of Intra-Cellular Therapies, as Chief Executive Officer, effective immediately. The move lands months before the company&apos;s first pivotal Phase 3 data readout, http://www.streetinsider.com/Press+Releases/A+CEO+With+a+Proven+Track+Record+of+Success+in+Growing+and+Scaling+Biopharmaceutical+Companies+Just+Appointed+CEO+at+a+Clinical-Stage+Biotech%2C+Months+Before+Its+Pivotal+Phase+3+Readout/26871902.html Wed, 05 Aug 2026 10:25:00 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657 http://www.streetinsider.com/Press+Releases/A+CEO+With+a+Proven+Track+Record+of+Success+in+Growing+and+Scaling+Biopharmaceutical+Companies+Just+Appointed+CEO+at+a+Clinical-Stage+Biotech%2C+Months+Before+Its+Pivotal+Phase+3+Readout/26871902.html <p>NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EVBnQJAQsrz9ukBZrfuPuBjVxM6i3OWBd4MRJKVWg4hKLDKGEf01sBMmQu0kgYoavoxMpwGjsak3drjd-H_UAEfD6hFAvD6jT4o8sPtfAA4=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>In biotech, the gap between a promising drug and a commercial success is often bridged by a single thing: the operator who has done it before. Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage company developing novel treatments for depression and anxiety, has just brought in exactly that kind of operator, appointing Michael Halstead, the former President of Intra-Cellular Therapies, as Chief Executive Officer, effective immediately. The move lands months before the company&apos;s first pivotal Phase 3 data readout, http://www.streetinsider.com/Press+Releases/A+CEO+With+a+Proven+Track+Record+of+Success+in+Growing+and+Scaling+Biopharmaceutical+Companies+Just+Appointed+CEO+at+a+Clinical-Stage+Biotech%2C+Months+Before+Its+Pivotal+Phase+3+Readout/26871902.html Wed, 05 Aug 2026 10:25:00 -0400 A.06822034 A.17471648 A.24598926 A.50216152 ATAI CMPS DFTX HELP HELP JNJ O.00000295 O.12458983 O.17008112 O.19241221 O.20026344 O.37286706 O.38546254 O.47928049 O.48309657